Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.94 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.94 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.94 |
| ▸ | TSHR | P16473 | 3/20 | 0.94 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.94 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.94 |
| ▸ | HTR2A | P28223 | 2/20 | 0.94 |
| ▸ | HTR2C | P28335 | 2/20 | 0.94 |
| ▸ | HRH1 | P35367 | 2/20 | 0.94 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.94 |
| ▸ | DRD3 | P35462 | 2/20 | 0.94 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.94 |
| ▸ | HTR2B | P41595 | 2/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.94 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.94 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL2209541 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL34268 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 0.97 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29528186 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL649168 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2206798 | 0.95 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP Pharmaceuticals, Inc. | 2025-12-09 | — | — | US | disclosed |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | OWP PHARMACEUTICALS INC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240197631-A1 | ATOMOXETINE ORAL SOLUTION | OWP Pharmaceuticals, Inc. | 2024-06-20 | — | — | US | disclosed |
| CN-115778895-B | Atomoxetine hydrochloride oral solution | 江苏广承药业有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-01-25 | — | — | US | disclosed |
| CN-117440816-A | Modified MIR-135, conjugated forms thereof and uses thereof | 耶达研究及发展有限公司 | 2024-01-23 | — | — | CN | disclosed |
| EP-2911695-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2023-11-29 | — | — | EP | disclosed |
| EP-4277635-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | Yeda Research and Development Co. Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| CN-115721634-B | Atomoxetine hydrochloride composition, preparation method thereof and application thereof in oral solution | 海南卓科制药有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-115778895-A | Tomoxetine hydrochloride oral solution | 江苏广承药业有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2011131693-A2 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | NLIFE THERAPEUTICS, S.L. (ES) | 2011-10-27 | — | — | WO | disclosed |
| EP-2380595-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | Nlife Therapeutics S.L. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-8041258-B2 | Process cartridge and image forming apparatus | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20110132812-A1 | Separation and Manipulation of a Chiral Object | KIBAR OSMAN | 2011-06-09 | — | — | US | disclosed |
| US-7935906-B2 | Separation and manipulation of a chiral object | DYNAMIC CONNECTIONS, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080274555-A1 | Applying electricity; rotation; for sugars, proteins, peptides | DYNAMIC CONNECTIONS, LLC (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080262240-A1 | Separation And Manipulation Of A Chiral Object | DYNAMIC CONNECTIONS, LLC | 2008-10-23 | — | — | US | disclosed |
| WO-2008026227-A2 | A PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491157-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | SLC6A2 5/4885SLC6A4 1/4885CYP1A2 1334/4885 |
| US-20080262240-A1 | Separation And Manipulation Of A Chiral Object | DCX, RAC3, COIL | SLC6A2 2637/4885SLC6A4 2673/4885CYP1A2 4832/4885 |
| US-12478584-B1 | Atomoxetine hydrochloride oral suspension and use thereof | SLC6A4, SLC6A3, MBOAT4 | SLC6A2 5/4885SLC6A4 1/4885CYP1A2 1334/4885 |
| US-20240197631-A1 | ATOMOXETINE ORAL SOLUTION | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 1/4885CYP1A2 229/4885 |
| US-20240026357-A1 | MODIFIED MIR-135, CONJUGATED FORM THEREOF, AND USES OF SAME | METTL16, SYNCRIP, FBL | SLC6A2 3147/4885SLC6A4 3126/4885CYP1A2 4279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.